The global Neurology Clinical Trials Market was valued at USD 6.25 billion in 2025 and is projected to grow from USD 6.60 billion in 2026 to USD 10.26 billion by 2034, expanding at a CAGR of 5.67% during the forecast period (2026–2034), according to the latest analysis by Straits Research.

The neurology clinical trials sector continues to gain momentum as pharmaceutical companies, biotechnology firms, contract research organizations (CROs), and healthcare institutions intensify efforts to develop treatments for neurological disorders. Growing prevalence of Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, stroke, epilepsy, amyotrophic lateral sclerosis (ALS), and traumatic brain injuries is creating strong demand for innovative neurological therapies and clinical research programs.

In parallel, increasing venture capital investments in neuroscience, advancements in precision medicine, and the adoption of patient-centric clinical trial technologies are transforming the landscape of neurological drug development worldwide.

Market Dynamics & Core Insights

Rising Prevalence of Neurological Disorders Fuels Market Expansion

The growing global burden of neurological diseases remains one of the primary factors driving demand for neurology clinical trials. Increasing life expectancy and aging populations have contributed significantly to the prevalence of dementia, Alzheimer’s disease, Parkinson’s disease, stroke, and peripheral neuropathy.

Major pharmaceutical companies continue to prioritize neuroscience research despite historical challenges in late-stage clinical development. Recent breakthroughs in Alzheimer’s disease treatment and approvals for therapies targeting spinal muscular atrophy have renewed confidence in neurological drug development and accelerated investment across the sector.

Growing research expenditures and strategic collaborations between biotechnology companies, pharmaceutical manufacturers, academic institutions, and CROs are further supporting market growth.

Limited Understanding of Neurological Disease Biology Remains a Challenge

Despite significant advances in neuroscience, the complexity of neurological disorders continues to pose substantial challenges for researchers. Limited access to brain tissue, insufficient disease biomarkers, and a lack of validated molecular targets hinder drug discovery efforts and clinical development timelines.

Psychiatric and neurological disorders often involve highly complex biological pathways, making it difficult to develop effective therapies and predictive disease models. Consequently, high failure rates in late-stage clinical trials remain a major obstacle for industry stakeholders.

Technological Innovations Transform Clinical Trial Efficiency

The integration of advanced technologies is reshaping neurology clinical trials by improving patient recruitment, retention, monitoring, and data collection.

Virtual clinical trials, decentralized trial models, wearable devices, digital biomarkers, remote patient monitoring, and artificial intelligence-powered analytics are enhancing trial efficiency while reducing participant burden. These innovations are helping researchers collect real-world evidence more effectively and improve patient engagement throughout the clinical trial process.

As healthcare systems increasingly embrace digital transformation, technology-enabled neurology trials are expected to become a key growth driver over the coming decade.

Regional Analysis

North America Maintains Market Leadership

North America continues to dominate the global neurology clinical trials market, accounting for the largest revenue share. The region benefits from a strong pharmaceutical and biotechnology ecosystem, advanced healthcare infrastructure, substantial research funding, and a growing prevalence of neurological disorders.

The United States remains a major contributor to market growth, supported by increasing investments in neuroscience research and a rapidly aging population. The anticipated rise in Alzheimer’s disease and dementia cases is expected to create sustained demand for neurological clinical studies across the region.

Middle East and Africa Emerges as the Fastest-Growing Region

The Middle East and Africa (MEA) market is projected to register the highest growth rate during the forecast period. Rising incidences of neurological, psychiatric, developmental, and substance-use disorders are increasing demand for clinical research activities across the region.

Growing healthcare investments, improving research infrastructure, and heightened awareness regarding neurological health are expected to support long-term market expansion. Additionally, increasing prevalence of stroke, depression, post-traumatic stress disorder (PTSD), and neurodegenerative diseases presents significant opportunities for clinical trial sponsors and CROs.

Segment Highlights

By Phase

• Phase II dominated the market and accounted for the largest revenue share due to the high volume of neurological drug candidates undergoing efficacy evaluation.
• Phase III is expected to witness the fastest growth owing to increasing investments in late-stage clinical development and larger patient enrollment requirements.

By Study Design

• Interventional studies led the market, representing the majority of registered neurology clinical trials globally.
• Observational studies are anticipated to experience significant growth due to their expanding role in post-marketing surveillance, real-world evidence generation, and long-term treatment outcome assessments.

By Indication

• Huntington’s Disease is projected to record the fastest growth rate during the forecast period due to increasing disease prevalence, rising research investments, and growing clinical trial activity.
• Additional high-priority therapeutic areas include Parkinson’s disease, epilepsy, stroke, ALS, traumatic brain injury, and muscle regeneration therapies.

Key Market Players

1. IQVIA
2. Novartis
3. Covance
4. Medpace
5. Charles River Laboratories
6. Syneos Health
7. ICON plc
8. GlaxoSmithKline (GSK)
9. Aurora Healthcare
10. Biogen

• Biogen remains one of the industry’s leading neuroscience-focused organizations, driving innovation in Alzheimer’s disease, multiple sclerosis, spinal muscular atrophy, and other neurological conditions.

Industry Impact and Future Outlook

The neurology clinical trials market is entering a transformative era characterized by scientific innovation, digital health integration, and increased investment in neuroscience research. Growing understanding of neurological disease mechanisms, combined with advancements in biomarkers, genomics, artificial intelligence, and decentralized clinical trial technologies, is expected to improve trial success rates and accelerate therapeutic development.

Over the next decade, increasing demand for treatments targeting neurodegenerative diseases, rare neurological disorders, and age-related cognitive conditions will continue to create substantial opportunities for pharmaceutical companies, biotechnology firms, CROs, and healthcare providers worldwide.

Gain access to expanded insights on competitive strategies, market size, and regional analysis. View our Market Report Overview here: https://straitsresearch.com/report/neurology-clinical-trials-market

About Straits Research

Straits Research is a leading global market intelligence and consulting firm specializing in delivering actionable research insights, industry forecasts, competitive intelligence, and strategic advisory services across diverse sectors. Through rigorous methodologies, comprehensive data analysis, and extensive industry expertise, Straits Research helps organizations identify emerging opportunities, navigate market complexities, and make informed business decisions. The company serves clients across North America, Europe, Asia-Pacific, the Middle East & Africa, and Latin America with reliable, data-driven market intelligence solutions.